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Letters to the EditorWeyland and colleagues4 described a
laboratory validation in a pediatric setting
comparing the Deltatrac system with mass
spectrometry and wet gas spirometry. They
found a mean bias of 3.2 % (SD 11.5 %),
including the following conditions: FIO2
(inspired oxygen fraction) 0.21 to 0.8, FIO2-
FEO2 (expired oxygen fraction) 0.01 to
0.05, VE (expired volume) 300 to 6000
mL/min, VT (tidal volume) 8 to 300 mL,
Paw (airway opening pressure) 10 to 60
mbar, and relative humidity 10% to 60%.4
These wide ranges of respiratory variables
might explain the wider ranges of the stan-
dard deviation.
Bauer and colleagues5 performed an in
vitro validation and clinical testing for venti-
lated preterm infants. In vitro validation was
done by methanol burning during intermit-
tent positive-pressure ventilation (IPPV) with
two commonly used ventilators: Sechrist
IV 100B (Sechrist Industries, Anaheim,
Calif) and the Infant star software version
83 (Nellcor Puritan Bennet Inc, Carlsbad,
Calif). They found a mean difference be-
tween VO2 measurements using the Delta-
trac II system and VO2 determined by the
methanol burning method from 2% to 2 %
(max SD  5%) depending on the ventilator
and peak inspiratory pressure they used.
For clinical testing, they developed a
breath collector to avoid gas leakage around
uncuffed endotracheal tubes or during na-
sal continuous positive airway pressure
(CPAC). This test arrangement simulta-
neously sampled expired air expelled at the
ventilator and escaping via the tube leak
from the infant=s mouth and nose and al-
lowed VO2 measurements that are not af-
fected by tube leaks.
They studied 15 preterm infants during
IPPV and 10 preterm infants during nasal
CPAP and determined a mean difference of
VO2 of 6.5 (SD 1.5) mL · kg1 · min1
during IPPV and 6.6 (SD 2.2) mL · kg1 ·
min1 during nasal CPAP.
In conclusion, these studies prove that
the Deltatrac II system is a feasible and
reliable device to measure VO2 in venti-
lated infants if air leaks can be excluded.
We determined air leak by measuring
inspiratory and expiratory tidal volume us-
ing the features of the ventilator (Siemens
Servo Ventilator 900 D; Siemens, Erlan-
gen, Germany). As described in the Meth-
ods section, we had to exclude 12 patients
because of air leakage of more than 5%.
TFinally, Berger and Bergstra correctly
pointed out that a shunt ratio can be calcu-
lated using oxygen saturation measurements.
A determination of pulmonary or systemic
blood flow is necessary to calculate abso-
lute shunt volumes.
U. Fakler, MD
J. Hess, MD
German Heart Center
Department of Pediatric Cardiology and
Congenital Heart Disease
Technische Universität München
Munich, Germany
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Triiodothyronine in neonatal heart
surgery: Looking for an answer
To the Editor:
We congratulate Mackie and colleagues1
on their randomized study on triiodothyro-
dine (T3) treatment in neonatal heart sur-
gery. In their study group the authors cor-
rectly enrolled a homogenous group of
infants at highest risk of postoperative low
cardiac output syndrome and marked thy-
roid hormone suppression.2 As already
shown by several other authors, the thyroid
hormone levels are suppressed after cardio-
pulmonary bypass (CPB), decreasing to a
nadir at around 48 hours after CPB and re-
covering over approximately 1 week. Logi-
cally, treatment with T3 after CPB raises the
T3 plasma concentrations to normal levels,
and no negative effects have been demon-
strated so far. Previous studies, as well as
he Journal of Thoracic and Cardiovascularthe study presented, had relatively small
subject numbers, thereby limiting the abil-
ity to determine a clinical effect. This led to
the initiation of the Triiodothyronine for
Infants and Children Undergoing Cardio-
pulmonary Bypass (TRICC) study, a ran-
domized, multicenter clinical trial designed
to determine safety and efficacy of T3 sup-
plementation in children less than 2 years
of age undergoing surgical procedures for
congenital heart disease.3
We would, however, counsel some cau-
tion in the interpretation of the main results
of this study mainly for two reasons:
First, to our knowledge many centers
worldwide would use in these patients peri-
toneal dialysis (PD) in the early postoper-
ative phase to minimize the effects of sys-
temic inflammatory response and achieve
adequate fluid balance.4 Usually peritoneal
catheters are placed at the end of the oper-
ation to drain excess fluid as a routine
institutional procedure, and PD is started
after admission to the intensive care unit
either on a prophylactic basis or after oli-
guria, anuria, fluid overload, hyperkalemia,
or acidosis. PD is able to achieve ade-
quate negative fluid balance in nearly all
instances and treat other underlying
causes simultaneously. Thus the positive
achievement of negative fluid balance at
day 2 versus day 2.5 may be clinically
negligible under most given circum-
stances.
Second, the authors quote the effect of
the T3 infusion on the cardiac output, systolic
blood pressure and, herewith, indirectly on
the requirements of catecholamines. Unfortu-
nately, no information is provided on the
absolute use of vasodilators (such as phe-
noxybenxzamine, sodium nitroprusside, and
milrinone), nor is there differentiation in the
catecholamine use with regard to dopamine.
It is widely known that dopamine has a direct
negative effect on thyroid function and thy-
roid hormone levels in infants and children.5
Other factors such as the use of amiodarone
should be discussed too. Finally, the overall
dropout rate of cardiac output measurements
in both groups (14/42) seems relatively high
and unbalanced between the two small study
groups. This additional information seems
crucial to enable a more objective assessment
of the study.
Despite these limitations, we believe
that the study by Mackie and associates
adds valuable information to the contro-
versial dispute on the efficiency of T3 as
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Letters to the Editoran inotropic agent after CPB. However,
we hope some of the questions may be
answered by the results of the TRICC
study.
Nikolaus A. Haas
Christoph K. Camphausen
Paediatric Cardiac Intensive Care
The Prince Charles Hospital
Brisbane, Queensland, Australia
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Reply to the Editor:
We appreciate the interest of Haas and
Camphausen in our recently published trial
of triiodothyronine (T3) in neonatal heart
surgery.1 The points they raised are ad-
dressed below.
Our center, like many other centers per-
forming infant heart surgery in the United
States, routinely uses high-dose intrave-
nous loop and thiazide diuretics rather than
peritoneal dialysis to manage postoperative
fluid overload. We agree that the results of
our study cannot be generalized to patients
who are treated with peritoneal dialysis.
The inotrope score used in our study,
adapted from Wernovsky and associates,2
was determined by the use of dopamine,
dobutamine, milrinone, epinephrine, and
norepinephrine. The cumulative dose of
dopamine in particular did not differ be-
tween treatment groups during the first 5
days after the operation. Vasodilator use
506 The Journal of Thoracic and Cardiovawas also similar between treatment groups:
milrinone was used routinely in our pa-
tients, with no difference in cumulative
milrinone dose between treatment arms at
5 days. A single patient (randomized to the
T3 group) received nitroprusside; no pa-
tients received phenoxybenzamine. Amio-
darone was not used in any subject.
We planned our trial so that cardiac
output was one of two primary outcome
measures. The technique used (direct mea-
surement of oxygen consumption by real-
time gas exchange) provides an objective
determination of cardiac output in children
who are sedated, ventilated, and stable.3
During the study period, infants were
weaned from mechanical ventilation at in-
creasingly shorter times after surgery, ren-
dering this measurement infeasible at 48
hours after surgery in several subjects.
However, the proportion of patients in each
treatment group in whom this end point
could not be measured (9/22 in the T3
group and 5/20 in the placebo group) was
not statistically significant (P  .34).
Andrew S. Mackie, MD, SM, FRCP(C)
Division of Cardiology
The Montreal Children’s Hospital
Montreal, Quebec, Canada
Stephen J. Roth, MD, MPH
Director, Cardiovascular Intensive Care
Lucile Packard Children’s Hospital
Stanford, Calif
Jane W. Newburger, MD, MPH
Associate Cardiologist-in-Chief
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Boston, Mass
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To the Editor:
I read with great interest the recently pub-
lished study by Fakler and associates1 in
the August 2005 issue of the Journal. They
found, in their investigation, a poor agree-
ment between the measured oxygen con-
sumption (VO2) and the VO2 estimated
using the formulas of Krovetz and Gold-
bloom2 and LaFarge and Miettinen.3 Ac-
cording to the Krovetz-Goldbloom for-
mula, the mean difference was 53 mL/
min/m2 and the limits of agreement were
95.5 and11.1 mL/min/m2 for the lower
and upper limits, respectively. Use of the
Krovetz-Goldbloom formula led to a sys-
tematic and significant overestimation in
VO2 values (P  .0001). However, a sig-
nificant correlation was shown between
measured and assumed VO2 values with
this formula (R .61; P .0001). Accord-
ing to the LaFarge-Miettinen formula, the
mean difference was 15.6 mL/min/m2
and the limits of agreement were 120.0
and 88.8 mL/min/m2 for the lower and
upper limits, respectively. A systematic
and significant overestimation was also re-
ported using the LaFarge-Miettinen for-
mula. A significant correlation was, how-
ever, indicated between measured and
assumed VO2 with this model (R  0.38;
P  .0037). I speculated that the reason
that the measured VO2 values were signif-
icantly different from the assumed VO2
using both Krovetz-Goldbloom and Lafarge-
Miettinen formulas was because of a meth-
odologic weakness in statistics and modeling.
As discussed by the authors, these dif-
ferences between measured VO2 and VO2
estimated by the formulas might be due to
a difference of population. I agree with this
statement, but more credible is the argu-
ment that these differences are explained
by the coefficients of these formulas
(Krovetz-Goldbloom formula: VO2  a ·
height b · weight c; Lafarge-Miettinen
formula: VO2  a=  b= · ln(age)  c= ·
heart rate for male subjects and VO2 
a= b · ln(age) c= · heart rate for female
subjects). These coefficients (a, b, c and a=,
b=, b and c=) depend on the characteristics
of the population included in the study.
That is why the use of published formulas
without any coefficient correction cannot
be applied in other populations, as shown
in another study.4 To overcome this prob-
lem, new formulas with new coefficients
should be calculated from the population
